Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:4464 |
Name | collecting duct carcinoma |
Definition | A renal cell carcinoma that begins in distal collecting ducts of the kidney with a tubulopapillary morphology and intracytoplasmic mucicarminophilic material. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer urinary system cancer kidney cancer renal carcinoma renal cell carcinoma collecting duct carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
ATM negative | Elimusertib | collecting duct carcinoma | predicted - sensitive | detail... |
BRAF G466A | Dabrafenib + Trametinib | collecting duct carcinoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02601937 | Phase I | Tazemetostat | A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma | Completed | USA | NLD | ITA | GBR | FRA | DNK | DEU | CAN | AUS | 0 |
NCT02601950 | Phase II | Tazemetostat | A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma | Completed | USA | ITA | GBR | FRA | DEU | CAN | BEL | AUS | 1 |
NCT02915783 | Phase II | Everolimus + Lenvatinib | A Phase 2 Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease | Completed | USA | 0 |
NCT03587662 | Phase II | Gemcitabine + Ixazomib Doxorubicin + Gemcitabine + Ixazomib | Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer | Active, not recruiting | USA | 0 |
NCT03866382 | Phase II | Cabozantinib + Nivolumab Cabozantinib + Ipilimumab + Nivolumab | Cabozantinib in Combination With Nivolumab and Ipilimumab in Rare Genitourinary Tumors | Recruiting | USA | 1 |
NCT04071223 | Phase II | Cabozantinib + Radium Ra 223 dichloride Cabozantinib | Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, the RadiCaL Study | Recruiting | USA | 0 |
NCT04413123 | Phase II | Cabozantinib + Ipilimumab + Nivolumab | Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC | Recruiting | USA | 0 |
NCT05286801 | Phase Ib/II | Atezolizumab + Tiragolumab | Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors | Recruiting | USA | CAN | AUS | 0 |
NCT05347212 | Phase II | Nivolumab + Relatlimab | Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla | Active, not recruiting | USA | 0 |
NCT06302569 | Phase II | Enfortumab vedotin-ejfv + Pembrolizumab | Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma (REPRINT) | Not yet recruiting | ITA | 0 |
NCT06444880 | Phase II | Cemiplimab + REGN4018 REGN4018 | Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies | Recruiting | USA | 0 |